Sulforaphane prevents diabetes‐induced hepatic ferroptosis by activating Nrf2 signaling axis

• Published in: BioFactors (Oxford) 2024-07, Vol.50 (4), p.810-827
• Main Authors: Savic, Nevena, Markelic, Milica, Stancic, Ana, Velickovic, Ksenija, Grigorov, Ilijana, Vucetic, Milica, Martinovic, Vesna, Gudelj, Andjelija, Otasevic, Vesna
• Format: Article
• Language: English
• Subjects: Animals; Antioxidants - pharmacology; diabetes; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - metabolism; ferritinophagy; ferroptosis; Ferroptosis - drug effects; GSH metabolism; iron metabolism; Isothiocyanates - pharmacology; Liver - drug effects; Liver - metabolism; Liver - pathology; Male; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2 - genetics; NF-E2-Related Factor 2 - metabolism; Nrf2; Oxidative Stress - drug effects; Signal Transduction - drug effects; sulforaphane; Sulfoxides
• ISSN: 0951-6433; 1872-8081; 1872-8081
• DOI: 10.1002/biof.2042

Recently, we characterized the ferroptotic phenotype in the liver of diabetic mice and revealed nuclear factor (erythroid‐derived‐2)‐related factor 2 (Nrf2) inactivation as an integral part of hepatic injury. Here, we aim to investigate whether sulforaphane, an Nrf2 activator and antioxidant, prevents diabetes‐induced hepatic ferroptosis and the mechanisms involved. Male C57BL/6 mice were divided into four groups: control (vehicle‐treated), diabetic (streptozotocin‐induced; 40 mg/kg, from Days 1 to 5), diabetic sulforaphane‐treated (2.5 mg/kg from Days 1 to 42) and non‐diabetic sulforaphane‐treated group (2.5 mg/kg from Days 1 to 42). Results showed that diabetes‐induced inactivation of Nrf2 and decreased expression of its downstream antiferroptotic molecules critical for antioxidative defense (catalase, superoxide dismutases, thioredoxin reductase), iron metabolism (ferritin heavy chain (FTH1), ferroportin 1), glutathione (GSH) synthesis (cystine‐glutamate antiporter system, cystathionase, glutamate‐cysteine ligase catalitic subunit, glutamate‐cysteine ligase modifier subunit, glutathione synthetase), and GSH recycling ‐ glutathione reductase (GR) were reversed/increased by sulforaphane treatment. In addition, we found that the ferroptotic phenotype in diabetic liver is associated with increased ferritinophagy and decreased FTH1 immunopositivity. The antiferroptotic effect of sulforaphane was further evidenced through the increased level of GSH, decreased accumulation of labile iron and lipid peroxides (4‐hydroxy‐2‐nonenal, lipofuscin), decreased ferritinophagy and liver damage (decreased fibrosis, alanine aminotransferase, and aspartate aminotransferase). Finally, diabetes‐induced increase in serum glucose and triglyceride level was significantly reduced by sulforaphane. Regardless of the fact that this study is limited by the use of one model of experimentally induced diabetes, the results obtained demonstrate for the first time that sulforaphane prevents diabetes‐induced hepatic ferroptosis in vivo through the activation of Nrf2 signaling pathways. This nominates sulforaphane as a promising phytopharmaceutical for the prevention/alleviation of ferroptosis in diabetes‐related pathologies. Graphical presentation of antiferroptotic acting of sulforaphane on diabetic liver through activation of Nrf2 and its signaling axis. Created with BioRender.com.